ACATOTCServices-Educational ServicesFiscal year ends December 31
NP Life Sciences Health Industry Group Inc.
Financials through Q4 FY2023, quarter ended Dec 31, 2023Last filing: 10-K on Apr 16, 2024
$10.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $429.60M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2023
Operating margin
-0.4%
Net margin
-1.8%
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +61.4% | +122.2% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | – | |
| Return on assets | – | – | -2.9% | |
| Interest coverage | – | – | -1.1× | |
| Diluted shares | – | – | 43M |
Cash use needs five years of cash flow figures
NP Life Sciences Health Industry does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-18.5%
×Asset turnover1.23×
×Equity multiplier2.89×
=Return on equity, FY2022-65.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -18.5% | 1.23× | 2.89× | -65.6% |
| FY2021 | -187.7% | 0.45× | 1.11× | -92.5% |
| FY2020 | -873.8% | 0.08× | 1.09× | -77.4% |
| FY2019 | -253.1% | 0.34× | 1.17× | -101.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
2of 6 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.94K
- Cash generatingOperating cash flow above zero-$73.61K
- Return on assets improvedROA up on the prior year-49.1% → -2.3%
- Earnings backed by cashOperating cash flow above net income-$73.61K vs -$2.94K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise43M → 43M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose2.66 → 1.29